Skip to content

Sophia Genetics

US · SOPH #3618 by market cap Listed 2021
6.92 -0.23 -3.22%
Live - 5344 symbols - heartbeat 267s ago · 2026-10-08 09:58
Pre-market 7.15 0.00%
After-hours 7.15 0.00%
Overnight 7.15 0.00%
Market cap
589.08M
P/B
7.09
EPS
-1.17
Reader sentiment Are you bullish or bearish on SOPH?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Ownership Signal how this is computed

Mixed / stable
  • Total institutional ownership (as a % of shares) was little changed.

Institutional ownership

Held by institutions
62.01% +0.02pp
Institutions
80
As of
2026/Q3 vs. prior period

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Holder types

Mutual Fund30.23%
VC/PE Fund18.59%
Hedge Fund9.93%
Individual/Insider8.51%
Private Company3.12%
Public Company0.11%
Other29.48%

Top holders as of 2026-02-15

Alychlo NV 8.22% · 6.99M sh
Generation Investment Management LLP 7.98% · 6.79M sh
aMoon Ventures Y.SH. Ltd 6.47% · 5.51M sh
Aigh Capital Management, LLC 4.65% · 3.95M sh
Akre Capital Management, LLC 4.37% · 3.72M sh
Jurgi Camblong 4.04% · 3.44M sh
Royce & Associates, LP 3.97% · 3.38M sh
Balderton Capital (UK) LLP 3.88% · 3.30M sh
Principal Global Investors, LLC 2.78% · 2.36M sh
Columbia Management Investment Advisers, LLC 2.60% · 2.22M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 0 buys · 50 sells

NameRoleStake
Jurgi Camblong Chief Executive Officer 4.04%
Ross Muken Chief Financial Officer 0.79%
Zhenyu Xu Chief Scientific Officer 0.65%
Vincent Ossipow Independent Non-Executive Director 0.59%
Daan van Well Executive VP, Chief Legal Officer & General Counsel 0.40%
Troy Cox Independent Non-Executive Chairperson 0.36%
George Cardoza Chief Financial Officer 0.36%
Didier Hirsch Independent Non-Executive Director 0.26%
Philippe Menu Executive VP, Chief Medical Officer & Chief Product Officer 0.24%
Jean-Michel Yves Cossery Director 0.22%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-04 George Cardoza Chief Financial Officer Intent to Sell (Form 144) -1,592 $8.07
2026-10-04 Jurgi Camblong Chief Executive Officer Intent to Sell (Form 144) -65,672 $8.07
2026-10-04 Zhenyu Xu Chief Scientific Officer Intent to Sell (Form 144) -19,394 $8.07
2026-10-04 Manuela Da Valente Chief Human Resources Officer Intent to Sell (Form 144) -4,240 $8.07
2026-10-04 Philippe Menu Executive VP, Chief Medical Officer & Chief Product Officer Intent to Sell (Form 144) -22,394 $8.07
2026-09-20 Ross Muken Chief Financial Officer Automatic Disposition -422 $8.33
2026-09-20 George Cardoza Chief Financial Officer Automatic Disposition -774 $8.33
2026-09-13 Zhenyu Xu Chief Scientific Officer Automatic Disposition -4,000 $7.88
2026-09-13 Philippe Menu Executive VP, Chief Medical Officer & Chief Product Officer Automatic Disposition -5,000 $7.88
2026-09-10 Daan van Well Executive VP, Chief Legal Officer & General Counsel Automatic Disposition -6,168 $7.63
2026-09-09 Jurgi Camblong Chief Executive Officer Automatic Disposition -8,500 $7.66
2026-09-07 Kathy Hibbs Independent Non-Executive Director Automatic Disposition -6,250 $8.13
2026-08-26 Zhenyu Xu Chief Scientific Officer Automatic Disposition -10,000 $8.91
2026-08-24 Kathy Hibbs Independent Non-Executive Director Automatic Disposition -6,250 $8.68
2026-08-24 Philippe Menu Executive VP, Chief Medical Officer & Chief Product Officer Automatic Disposition -5,000 $8.68
2026-08-23 Abhimanyu Verma Chief Technology Officer Automatic Disposition -10,000 $8.20–8.80
2026-08-20 Zhenyu Xu Chief Scientific Officer Automatic Disposition -20,000 $7.94–8.41
2026-08-19 Zhenyu Xu Chief Scientific Officer Intent to Sell (Form 144) -6,000 $8.28
2026-08-18 Zhenyu Xu Chief Scientific Officer Intent to Sell (Form 144) -8,000 $7.62
2026-08-18 Manuela Da Valente Chief Human Resources Officer Derivative Exercise and Sale -10,000 $3.20–7.94

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-10-08 09:58:23 · For reference only, not investment advice and not tailored to your situation.